ENDRA Life Sciences Inc

(NASDAQ:NDRA)

Latest On ENDRA Life Sciences Inc (NDRA):

Date/Time Type Description Signal Details
2023-05-16 02:35 ESTNewsEndra Life Sciences GAAP EPS of -$0.93 beats by $0.11N/A
2023-05-16 02:35 ESTNewsENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call TranscriptN/A
2023-04-28 22:03 ESTNewsENDRA Life Sciences prices stock and warrants offeringN/A
2023-03-14 23:32 ESTNewsEndra Life Sciences GAAP EPS of $1.04 beats by $1.94N/A
2023-03-14 23:32 ESTNewsENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call TranscriptN/A
2022-11-15 05:25 ESTNewsEndra Life Sciences GAAP EPS of -$0.05N/A
2022-11-15 05:25 ESTNewsENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call TranscriptN/A
2022-11-12 08:31 ESTNewsEndra Life Sciences Q3 2022 Earnings PreviewN/A
2022-09-30 04:55 ESTNewsENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeksN/A
2022-08-24 23:57 ESTNewsENDRA Life Sciences receives European patent for TAEUS systemN/A
2022-08-16 11:23 ESTNewsENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-15 19:07 ESTNewsEndra Life Sciences GAAP EPS of $0.06 beats by $0.12N/A
2022-08-12 22:40 ESTNewsEndra Life Sciences Q2 2022 Earnings PreviewN/A
2022-06-29 02:24 ESTNewsENDRA Life Sciences rises on new U.S. patent for liver disease monitoring systemN/A
2022-05-13 22:57 ESTNewsENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 21:21 ESTNewsEndra Life Sciences GAAP EPS of -$0.07N/A
2022-05-12 02:32 ESTNewsEndra Life Sciences Q1 2022 Earnings PreviewN/A
2022-04-21 22:26 ESTNewsEndra Life Sciences raises $8.7M YTD from common stock sale through ATM equity facilityN/A
2022-03-30 21:27 ESTNewsEndra Life Sciences GAAP EPS of -$0.28N/A
2022-03-30 21:27 ESTNewsENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q4 2021 Earnings Call TranscriptN/A
2022-03-30 04:50 ESTNewsEndra Life Sciences Q4 2021 Earnings PreviewN/A
2022-03-08 17:17 ESTNewsEndra Life Sciences gets US patent for liver disease monitoring system TAEUSN/A
2022-01-25 00:02 ESTNewsENDRA forms research partnership in China to study TAEUS device in liver diseaseN/A
2021-11-16 04:58 ESTNewsENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-29 02:10 ESTNewsWarning: NDRA is at high risk of performing badlyN/A
2021-10-14 01:57 ESTNewsENDRA Life Sciences gets new US patent related to co's TAEUS systemN/A
2021-10-06 13:24 ESTNewsNDRA is at high risk of performing badlyN/A
2021-09-30 19:20 ESTNewsWarning: NDRA has been downgraded to Very BearishN/A
2021-09-23 08:05 ESTNewsWarning: NDRA has been downgraded to Very Bearish.N/A
2021-08-13 17:50 ESTNewsENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 16:48 ESTNewsENDRA Life Sciences names Irina Pestrikova Principal Financial OfficerN/A
2021-03-26 12:51 ESTNewsENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-25 18:02 ESTNewsEndra Life Sciences EPS beats by $0.08N/A
2021-02-23 04:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.17 to $4.75.Neutral
2021-01-20 21:18 ESTNewsNFLX, TELL, CLBS, and FUTU among notable pre-market gainersN/A
2021-01-14 06:47 ESTNewsENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technologyN/A
2021-01-06 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-12-22 06:14 ESTNewsENDRA Life Sciences renews GE Healthcare collaboration agreementN/A
2020-12-16 09:25 ESTNewsENDRA Life Sciences slumps in after hours on underwritten public offeringN/A
2020-12-16 09:25 ESTNewsEndra Life prices $5M-share offeringN/A
2020-12-04 06:51 ESTNewsENDRA Life Sciences teams up with the CHU Angers for TAEUS device studyN/A
2020-11-26 20:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 12:43 ESTAnalyst RatingThe Analyst Target Price has increased from $5.08 to $5.17.Buy
2020-11-19 12:49 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 20:36 ESTEarnings EstimateAn EPS average of -$0.14 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-17 15:00 ESTNewsEndra Life Sciences EPS beats by $0.02N/A
2020-11-17 15:00 ESTNewsENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 16:35 ESTFinancialsCompany financials have been released.Neutral
2020-10-06 17:38 ESTAnalyst RatingThe Analyst Target Price has increased from $4.63 to $5.08.Buy
2020-10-05 07:23 ESTInsider TradeRenaud Bertrand Maloberti has directly disposed of 10,000 shares and currently holds 76,580 shares.Sell

About ENDRA Life Sciences Inc (NDRA):

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NDRA Quotes by TradingView

See Advanced Chart

General

  • Name ENDRA Life Sciences Inc
  • Symbol NDRA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Full Time Employees 15
  • Fiscal Year EndDecember
  • IPO Date2017-05-09
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://www.endrainc.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 26.03
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.18
  • Return on Assets -172%
  • Return on Equity -603%
  • Earnings Per Share -$1.63
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 109.11 million
  • EBITDA -9065316
  • Analyst Target Price $4.75
  • Book Value Per Share $0.13
View More

Share Statistics

  • Shares Outstanding 37.59 million
  • Shares Float 22.67 million
  • % Held by Insiders 548%
  • % Held by Institutions 2.79%
  • Shares Short 446816
  • Shares Short Prior Month 373732
  • Short Ratio 0.16
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.3
  • 52 Week High $3.09
  • 52 Week Low $0.6
  • 50 Day Moving Average 2.35
  • 200 Day Moving Average 1.25
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ENDRA Life Sciences Inc (NDRA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ENDRA Life Sciences Inc (NDRA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-16$N/A-$0.15-$0.1713.44%
2020-06-302020-08-14$N/A-$0.20-$0.2725.93%
2020-03-312020-05-14$N/A-$0.29-$0.3413.43%
2019-12-312020-03-26$N/A-$1.20-$0.29-321.05%
2019-09-302019-11-13$N/A-$0.46-$0.34-35.29%
2019-06-302019-08-08$N/A-$0.31-$0.310%
2019-03-312019-05-14$N/A-$0.37-$0.30-23.33%
2018-12-312019-03-11$N/A-$0.32
2018-09-302018-09-30$N/A-$0.70
2018-06-302018-06-30$-6174-$0.47
2018-03-312018-03-31$6174-$0.72
2017-12-312017-12-31$7000-$0.58
2017-09-302017-09-30$287000-$0.23
2017-06-302017-06-30$58000-$0.59

ENDRA Life Sciences Inc (NDRA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ENDRA Life Sciences Inc (NDRA) Chart:

ENDRA Life Sciences Inc (NDRA) News:

Below you will find a list of latest news for ENDRA Life Sciences Inc (NDRA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ENDRA Life Sciences Inc (NDRA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest NDRA Trades:

Date Shares Price
Jun 13, 2022 6:18 PM EST100$0.26
Jun 13, 2022 6:20 PM EST200$0.2562
Jun 13, 2022 6:20 PM EST100$0.2569
Jun 13, 2022 6:21 PM EST100$0.255
Jun 13, 2022 6:33 PM EST100$0.2578

ENDRA Life Sciences Inc (NDRA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/0001209191-20-038682-index.htm
2020-01-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1681682/000000000020000371/0000000000-20-000371-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120005185/0001209191-20-005185-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120005187/0001209191-20-005187-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024209/0001209191-20-024209-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024211/0001209191-20-024211-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024213/0001209191-20-024213-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024214/0001209191-20-024214-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024215/0001209191-20-024215-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024216/0001209191-20-024216-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024217/0001209191-20-024217-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024218/0001209191-20-024218-index.htm
2020-04-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024483/0001209191-20-024483-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120024484/0001209191-20-024484-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120031547/0001209191-20-031547-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120031895/0001209191-20-031895-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120032219/0001209191-20-032219-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120032502/0001209191-20-032502-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120032826/0001209191-20-032826-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120032827/0001209191-20-032827-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120033102/0001209191-20-033102-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120035185/0001209191-20-035185-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120035436/0001209191-20-035436-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120035437/0001209191-20-035437-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120035438/0001209191-20-035438-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/0001209191-20-035439-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120038680/0001209191-20-038680-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120038681/0001209191-20-038681-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/0001209191-20-038682-index.htm
2020-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120042615/0001209191-20-042615-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120043430/0001209191-20-043430-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120053429/0001209191-20-053429-index.htm
2020-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1681682/000120919120055831/0001209191-20-055831-index.htm
2020-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420000453/0001654954-20-000453-index.htm
2020-01-22S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1681682/000165495420000665/0001654954-20-000665-index.htm
2020-01-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1681682/000165495420000666/0001654954-20-000666-index.htm
2020-01-28424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1681682/000165495420000845/0001654954-20-000845-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420002407/0001654954-20-002407-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420003330/0001654954-20-003330-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1681682/000165495420003346/0001654954-20-003346-index.htm
2020-03-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1681682/000165495420003349/0001654954-20-003349-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1681682/000165495420003391/0001654954-20-003391-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420003393/0001654954-20-003393-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420003787/0001654954-20-003787-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420003997/0001654954-20-003997-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1681682/000165495420004207/0001654954-20-004207-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420004473/0001654954-20-004473-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1681682/000165495420004632/0001654954-20-004632-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1681682/000165495420004633/0001654954-20-004633-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420005473/0001654954-20-005473-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1681682/000165495420005509/0001654954-20-005509-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420006146/0001654954-20-006146-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420006789/0001654954-20-006789-index.htm
2020-07-22PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1681682/000165495420007923/0001654954-20-007923-index.htm
2020-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420007924/0001654954-20-007924-index.htm
2020-08-03DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1681682/000165495420008321/0001654954-20-008321-index.htm
2020-08-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1681682/000165495420008698/0001654954-20-008698-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1681682/000165495420009164/0001654954-20-009164-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420009242/0001654954-20-009242-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420009423/0001654954-20-009423-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420009764/0001654954-20-009764-index.htm
2020-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420010426/0001654954-20-010426-index.htm
2020-09-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1681682/000165495420010480/0001654954-20-010480-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1681682/000165495420010481/0001654954-20-010481-index.htm
2020-01-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1681682/999999999520000169/9999999995-20-000169-index.htm

ENDRA Life Sciences Inc (NDRA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ENDRA Life Sciences Inc (NDRA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 548%
Institutional Ownership: 279%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-09Francois Roger MichelonChief Executive OfficerBuy123,064.00155,561.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024209/0001209191-20-024209-index.htm
2020-04-09Michael Milos ThorntonChief Technology OfficerBuy96,213.00215,963.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024211/0001209191-20-024211-index.htm
2020-04-09ANTHONY DIGIANDOMENICODirectorBuy42,857.00242,083.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024215/0001209191-20-024215-index.htm
2020-05-22ANTHONY DIGIANDOMENICODirectorBuy10,000.000.787,800.00252,083.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120031895/0001209191-20-031895-index.htm
2020-05-28ANTHONY DIGIANDOMENICODirectorBuy5,000.000.904,500.00276,509.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120032827/0001209191-20-032827-index.htm
2020-06-08ANTHONY DIGIANDOMENICODirectorBuy5,000.000.924,600.00281,509.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120035185/0001209191-20-035185-index.htm
2020-04-09Lou BaseneseDirectorBuy41,587.0041,587.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024484/0001209191-20-024484-index.htm
2020-04-09Alexander Y TokmanDirectorBuy42,857.0042,857.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024217/0001209191-20-024217-index.htm
2020-04-09Sanjiv Sam GambhirDirectorBuy42,857.0042,857.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024218/0001209191-20-024218-index.htm
2020-04-09Michael HarshDirectorBuy42,857.0052,857.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024216/0001209191-20-024216-index.htm
2020-05-21Lou BaseneseDirectorBuy10,000.000.717,100.0059,068.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120031547/0001209191-20-031547-index.htm
2020-05-26Lou BaseneseDirectorBuy10,000.000.828,200.0069,068.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120032219/0001209191-20-032219-index.htm
2020-10-01Renaud Bertrand MalobertiChief Commercial OfficerSell10,000.000.727,200.0076,580.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120053429/0001209191-20-053429-index.htm
2020-05-27Lou BaseneseDirectorBuy10,000.000.858,500.0079,068.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120032502/0001209191-20-032502-index.htm
2020-04-09Renaud Bertrand MalobertiChief Commercial OfficerBuy86,580.0086,580.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024214/0001209191-20-024214-index.htm
2020-05-28Lou BaseneseDirectorBuy10,000.000.919,100.0089,068.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120032826/0001209191-20-032826-index.htm
2020-05-29Lou BaseneseDirectorBuy10,000.000.909,000.0099,068.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120033102/0001209191-20-033102-index.htm
2020-04-09David R. WellsChief Financial OfficerBuy79,653.0099,653.00https://www.sec.gov/Archives/edgar/data/1681682/000120919120024213/0001209191-20-024213-index.htm